The following is a summary of the Thomson Reuters Corporation (TRI) Q3 2024 Earnings Call Transcript:
Financial Performance:
Thomson Reuters reported a 7% increase in third quarter organic revenues, exceeding expectations.
Adjusted EBITDA for the quarter decreased by 4% to $609 million, with a margin decline influenced by investments in AI.
Legal Professionals organic revenue grew 7%, driven by GenAI-enabled products like Westlaw Precision and CoCounsel.
Business Progress:
Thomson Reuters is accelerating investments in Generative AI, expecting to spend over $200 million annually for the next few years.
Launched CoCounsel 2.0 and introduced advanced features in AI-driven tools like Checkpoint Edge with CoCounsel and the Claims Explorer tool in Westlaw Precision.
Made strategic acquisitions such as Safe Sign Technologies and Materia to boost its AI capabilities.
Opportunities:
Generative AI offerings in products like Westlaw Precision and CoCounsel continue to gain traction.
The divestiture of the FindLaw business allows Thomson Reuters to focus more on its core offerings of content-enabled technology for legal professionals.
Risks:
Investments in AI and related acquisitions are expected to increase operating costs, impacting profitability in the short term.
Global Print revenue continues to decline as expected, part of a broader industry trend away from print media.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
下記はトムソンロイター(TRI)の2024年第3四半期決算説明会の要約です:
財務実績:
トムソンロイターは、第3四半期の有機売上高が7%増の報告をし、期待を上回りました。
四半期の調整後EBITDAは4%減の60900万ドルと報告され、AIへの投資が影響してマージンが低下しました。
法律関連プロフェッショナルの有機売上高はGenAIを活用したWestlaw PrecisionやCoCounselなどの製品に牽引され、7%成長しました。
ビジネスの進展:
トムソンロイターはGenerative AIへの投資を加速し、今後数年間で年間20000万ドル以上を投じる計画です。
CoCounsel 2.0を発表し、Westlaw PrecisionのClaims ExplorerツールやCoCounselとCheckPoint EdgeのようなAI駆動ツールに新しい高度な機能を導入しました。
安全符号テクノロジーやマテリアのような戦略的な買収を行い、人工知能の能力を向上させています。
機会:
リスク:
ヒント:より詳細な情報については、IRウェブサイトを参照してください。この記事は、投資家の参考のみであり、ガイダンスや推奨事項はありません。